CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 302 enrolled
Drug / intervention
REGN910-3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02712008
NCT02712008Phase 2Completed
CompareCT.gov

A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema

Regeneron Pharmaceuticals·interventional·Posted Mar 17, 2016·Updated Oct 3, 2018

In Brief

A Phase 2 clinical trial evaluating REGN910-3 and Intravitreal Aflibercept Injection (IAI) for Diabetic Macular Edema. Completed, enrolled 302 participants across 51 sites.

Detailed Summary

The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 17, 2016
Enrollment StartMar 2, 2016
Primary CompletionJul 10, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.3 years ago

Interventions

REGN910-3drug

Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intravitreal Aflibercept Injection (IAI)drug